Polyclonal and Monoclonal Antibodies to TPH1 and TPH2

Case ID:

This technology is a set of antibodies that is used with immunohistochemistry techniques to differentiate between tryptophan hydroxylase 1 and 2, enabling scientists to study how the two enzymes are differentially regulated.


Background & Unmet Need:

The tryptophan hydroxylase 1 and 2 (TPH1 and TPH2) genes encode enzymes in serotonin biosynthesis.  Variants in both genes have been implicated in several neuropsychiatric disorders and personality traits.  Prior to the discovery of TPH2 in 2003, it was thought that serotonin levels in the central nervous system were regulated by serotonin synthesis in the peripheral tissues, with TPH1 as the gene driving that mechanism.  The ability to differentiate between the two enzymes would allow scientists to study their different regulation mechanisms.


Technology Description:

WSU researchers have developed a group of monospecific polyclonal and monoclonal antibodies that allows for differentiation of TPH1 and TPH2 in immunoblotting, immunoprecipitation, and immunocytochemical staining. 


Commercial Applications:

  • Research agents used to differentiate between TPH1 and TPH2


Stage of Development:



Competitive Advantages:

  • Allows for studies of differential regulation of TPH1 and TPH2 expression in the brain and periphery


Intellectual Property Status:

No patent information available


Related Publications or Citations of Work:


Patent Information:
For Information, Contact:
Nicole Grynaviski
Commercialization Principal
Wayne State University
Donald Kuhn